title: [Survival of gout patients].
abstract: OBJECTIVE
  To assess survival and lethal outcome risk fahctors in gout patients.
  
  
  METHODS
  The study included 286 gout patients (246 males, 86% and 49 females, 14%) treated for gout in the Research Institute of Rheumatology from 2001 to 2006. From 2010 to May 2011 a telephone survey was made to obtain information about death of the above examinees. After the survey clinical condition of the dead patients was compared to that of survivors.
  
  
  RESULTS
  Of 286 participants of the trial, 38 did not response. By information from the relatives, there were 31 (12.5%) lethal outcomes of 248 patients. A cause of death in 20 patients, irrespective of age, were cardiovascular complications, 6 patients died of cancer; one patient--of chronic renal failure, one--of infection, one--of trauma and 2 - of unknown cause. Median of age at death was 62.1 years, median of gout duration--12.8 years. 65% of the deceased patients had risk factors of cardiovascular complications (type 2 diabetes mellitus, coronary heart disease, acute myocardial infarction, stroke, chronic cardiac failure). Median of time since examination in the clinic to death was 4.3 years.
  
  
  CONCLUSIONS
  Gout patients' mortality is high. 7-year survival was 85% in high overall mortality. 2/3 patients died of cardiovascular diseases. Survival of gout patients with normuricemia is the same ofthose with hyperuricemia. A high level of highly sensitive CRP is a factor of poor prognosis (death) for gout patients.
mesh_terms: D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality*; D003625:Data Collection; D005260:Female; D006073:Gout / Q000150:complications / Q000401:mortality* / Q000503:physiopathology; D006801:Humans; D033461:Hyperuricemia / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D017741:Survivors; D013997:Time Factors
chemical_list: D002097:C-Reactive Protein